Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Prophylaxis and Vaccinations for Infections with BCMA and GPRC5D T-Cell Engagers in Multiple Myeloma: Usmirc Practice Patterns

Ishita Kamboj, Chelsea Gorsline, Aneela Majeed, Dilek Ince, Jordan Snyder, Hira Shaikh, Abdullah Mohammad Khan, Kimberly M Green, Shebli Atrash, Faiz Anwer, Claire Yun Kyoung Ryu Tiger, Omar Alkharabsheh, Prerna Mewawalla, Al-Ola Abdallah, Barry Paul, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 7178.

https://doi.org/10.1182/blood-2024-208036

Published: 2024

Journal Articles

Impact of Absolute Lymphocyte Count on Efficacy and Toxicity of T-Cell Engagers in Non-Hodgkin's Lymphoma

Jordan Snyder, Nausheen Ahmed, Aqeeb Ur Rehman, Muhammad Umair Mushtaq, Aung M. Tun, Al-Ola Abdallah, Marc Hoffmann, Forat Lutfi

Blood (2024) 144 (Supplement 1): 7731.

https://doi.org/10.1182/blood-2024-207753

Published: 2024

Journal Articles

Efficacy of BCMA T-Cell Engagers (TCE) Vs. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Following BCMA-Directed Therapies, Relapsed/Refractory Multiple Myeloma: The Chicken or the Egg Dilemma

Blood (2024) 144 (Supplement 1): 7098.

https://doi.org/10.1182/blood-2024-207398

Published: 2024

Journal Articles

Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients

Blood (2024) 144 (Supplement 1): 5170.4.

https://doi.org/10.1182/blood-2024-211018

Published: 2024

Journal Articles

Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 7860.

https://doi.org/10.1182/blood-2024-210976

Published: 2024

Journal Articles

Real-World Incidence of Infections in BCMA-Targeting Bi-Specific Antibodies in Relapsed/Refractory Multiple Myeloma

Jordan Snyder, Jessica McElwee, Hailey Hill, Donald C Moore, Shebli Atrash, Myra Robinson, Ferdous Ahmed, Al-Ola Abdallah, Zahra Mahmoudjafari, Nausheen Ahmed, Grace Elsey

Blood (2024) 144 (Supplement 1): 7845.

https://doi.org/10.1182/blood-2024-208961

Published: 2024

Journal Articles

Outcomes of Double-Hit and Single High Risk Cytogenetic Newly Diagnosed Myeloma in Transplant Eligible Patients

Raeef L Rahman, Aroog Khaliq, Mehak M Laharwal, Shebli Atrash, Joseph P. McGuirk, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Al-Ola Abdallah, Nausheen Ahmed, Prerna Mewawalla, Jordan Snyder

Blood (2024) 144 (Supplement 1): 6953.

https://doi.org/10.1182/blood-2024-206098

Published: 2024

Journal Articles

Characterizing Treatment Patterns in Multiple Myeloma Patients with High-Risk Cytogenetics: A 15-Year-Study

Priyanka Venkatesh, Raeef L Rahman, Aroog Khaliq, Mehak M Laharwal, Shebli Atrash, Joseph P. McGuirk, Forat Lutfi, Muhammad Umair Mushtaq, Al-Ola Abdallah, Nausheen Ahmed, Prerna Mewawalla, Jordan Snyder, Zahra Mahmoudjafari

Blood (2024) 144 (Supplement 1): 6943.

https://doi.org/10.1182/blood-2024-211572

Published: 2024

Journal Articles

A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment

Alma Habib, Abdullah Mohammad Khan, Mehak M Laharwal, Prerna Mewawalla, Marshall McKenna, Yun Kyoung Tiger, Hira Shaikh, Christopher Strouse, Kimberly M Green, James A Davis, Hamza Hashmi, Jordan Snyder, Zahra Mahmoudjafari, Muhammad Umair Mushtaq, Nausheen Ahmed, Al-Ola Abdallah, Shebli Atrash, Barry Paul, Reed Friend

Blood (2024) 144 (Supplement 1): 7037.

https://doi.org/10.1182/blood-2024-209283

Published: 2024

Journal Articles

Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma

Blood (2024) 144 (Supplement 1): 2411.7.

https://doi.org/10.1182/blood-2024-204158

Published: 2024

Journal Articles

Use of Doublet Maintenance (Bortezomib-Lenalidomide) Vs Monotherapy Lenalidomide As Maintenance Therapy Post-Transplant of Patients with High-Risk Cytogenetics Myeloma

Mehak M Laharwal, Jordan Snyder, Aroog Khaliq, Raeef L Rahman, Shebli Atrash, Muhammad Umair Mushtaq, Al-Ola Abdallah, Nausheen Ahmed, Prerna Mewawalla

Blood (2024) 144 (Supplement 1): 7017.

https://doi.org/10.1182/blood-2024-201907

Published: 2024

Journal Articles

Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns

Ishita Kamboj, Jordan Snyder, Chelsea Gorsline, Dilek Ince, Aneela Majeed, Faiz Anwer, Hira Shaikh, Abdullah Mohammad Khan, Al-Ola Abdallah, Kimberly M Green, Shebli Atrash, Claire Yun Kyoung Ryu Tiger, Prerna Mewawalla, Barry Paul, Nausheen Ahmed

Blood (2024) 144 (Supplement 1): 5040.

https://doi.org/10.1182/blood-2024-208349

Published: 2024

Journal Articles

Real-World Experience of Infections with T-Cell Engagers in Multiple Myeloma and Non-Hodgkin's Lymphoma

Jordan Snyder, Dennis Grauer, Nausheen Ahmed, Al-Ola Abdallah, Marc Hoffmann, Zahra Mahmoudjafari

Blood (2024) 144 (Supplement 1): 935.

https://doi.org/10.1182/blood-2024-199893

Published: 2024

Journal Articles

Practical Implications of Multi-Institution Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity (ICANS) Rates in Lymphoma Targeted Bispecific Antibodies (BsAb)

Sara Leidy, Jordan Snyder, James A Davis, William Wesson, Brian Hess, Ryan Jacobs, Madalyn Edmonds, Nausheen Ahmed, Marc Hoffmann

Blood (2024) 144 (Supplement 1): 2350.

https://doi.org/10.1182/blood-2024-199658

Published: 2024

Journal Articles

Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma

James A Davis, Jordan Snyder, Mikhaila Rice, Donald C Moore, Christopher Cahoon, Kelley Julian, Charlotte B Wagner, Katelynn Granger, Kimberly M Green, Shebli Atrash, Hailey Hill, Jessica McElwee, Grace Elsey, Jack Khouri, Joslyn Rudoni, Zahra Mahmoudjafari, Victoria Nachar

Blood (2024) 144 (Supplement 1): 2382.

https://doi.org/10.1182/blood-2024-193025

Published: 2024

Journal Articles

Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Who Received at Least 2 BCMA-Directed Therapies

Jordan Snyder, Zain Alsaddi, Omar Alkharabsheh, Barry Paul, Forat Lutfi, Nausheen Ahmed, Zahra Mahmoudjafari, Al-Ola Abdallah, Shebli Atrash

Blood (2023) 142 (Supplement 1): 1969.

https://doi.org/10.1182/blood-2023-185231

Published: 2023

Journal Articles

Efficacy of Daratumumab-Based Regimens in Anti-CD38 Treatment-Naïve Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics

Jordan Snyder, Razan Mansour, Aytaj Mammadzadeh, Hamza Hashmi, Aimaz Afrough, Omar Alkharabsheh, Barry Paul, Shebli Atrash, Muhammad Umair Mushtaq, Barry S. Skikne, Nausheen Ahmed, Al-Ola Abdallah

Blood (2023) 142 (Supplement 1): 1985.

https://doi.org/10.1182/blood-2023-187487

Published: 2023

Journal Articles

Unusual Case of Hepatic Sinusoidal Obstruction Syndrome Induced By Low Dose Oral Cyclophosphamide

Pramod Gaudel, MD, Jordan Snyder, Pharm.D, Abdulraheem Yacoub, MD

Blood (2020) 136 (Supplement 1): 37.

https://doi.org/10.1182/blood-2020-141516

Published: 2020

NARROW

Prophylaxis and Vaccinations for Infections with BCMA and GPRC5D T-Cell Engagers in Multiple Myeloma: Usmirc Practice Patterns

Impact of Absolute Lymphocyte Count on Efficacy and Toxicity of T-Cell Engagers in Non-Hodgkin's Lymphoma

Efficacy of BCMA T-Cell Engagers (TCE) Vs. Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Following BCMA-Directed Therapies, Relapsed/Refractory Multiple Myeloma: The Chicken or the Egg Dilemma

Talquetamab in B Cell Maturation Antigen (BCMA) Exposed Relapsed-Refractory Multiple Myeloma Patients

Real-World Safety and Efficacy of Talquetamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

Real-World Incidence of Infections in BCMA-Targeting Bi-Specific Antibodies in Relapsed/Refractory Multiple Myeloma

Outcomes of Double-Hit and Single High Risk Cytogenetic Newly Diagnosed Myeloma in Transplant Eligible Patients

Characterizing Treatment Patterns in Multiple Myeloma Patients with High-Risk Cytogenetics: A 15-Year-Study

A Real-World Analysis of the Safety and Efficacy of Teclistamab for Patients with Relapsed/Refractory Multiple Myeloma and Baseline Renal Impairment

Evaluation of Teclistamab in BCMA-Directed Therapy Exposed Versus Naïve in Relapsed/Refractory Multiple Myeloma

Use of Doublet Maintenance (Bortezomib-Lenalidomide) Vs Monotherapy Lenalidomide As Maintenance Therapy Post-Transplant of Patients with High-Risk Cytogenetics Myeloma

Prophylaxis and Vaccinations for Infections with BCMA Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma: Usmirc Practice Patterns

Real-World Experience of Infections with T-Cell Engagers in Multiple Myeloma and Non-Hodgkin's Lymphoma

Practical Implications of Multi-Institution Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity (ICANS) Rates in Lymphoma Targeted Bispecific Antibodies (BsAb)

Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma

Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Who Received at Least 2 BCMA-Directed Therapies

Efficacy of Daratumumab-Based Regimens in Anti-CD38 Treatment-Naïve Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics

Unusual Case of Hepatic Sinusoidal Obstruction Syndrome Induced By Low Dose Oral Cyclophosphamide

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only